U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H14NO.C7H7O3S
Molecular Weight 311.3982
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FURTRETHONIUM TOSYLATE

SMILES

C[N+](C)(C)Cc1ccco1.Cc1ccc(cc1)S(=O)(=O)[O-]

InChI

InChIKey=QUAGBPHWBBENAF-UHFFFAOYSA-M
InChI=1S/C8H14NO.C7H8O3S/c1-9(2,3)7-8-5-4-6-10-8;1-6-2-4-7(5-3-6)11(8,9)10/h4-6H,7H2,1-3H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C8H14NO
Molecular Weight 140.2032
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H7O3S
Molecular Weight 171.195
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Furmethide

Approved Use

Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma
Doses

Doses

DosePopulationAdverse events​
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
Disc. AE: Dacryostenosis acquired...
AEs leading to
discontinuation/dose reduction:
Dacryostenosis acquired (71%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dacryostenosis acquired 71%
Disc. AE
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
PubMed

PubMed

TitleDatePubMed
Further studies on the use of furmethide in the treatment of glaucoma.
1946 Apr
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.
1947 Aug
Glaucoma treatment by furnethide and diisopropylfluorophosphate.
1949 Jul
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997 Jul
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Jun 26 04:39:55 UTC 2021
Edited
by admin
on Sat Jun 26 04:39:55 UTC 2021
Record UNII
15H5ION32Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FURTRETHONIUM TOSYLATE
Common Name English
UCEPHA-11001
Code English
FURTRETHONIUM P-TOLUENESULFONATE
MI  
Common Name English
TRIMETHYLFURFURYLAMMONIUM P-TOLUENESULFONATE
Common Name English
AMMONIUM, FURFURYLTRIMETHYL-, P-TOLUENESULFONATE
Common Name English
FISOSTINA
Brand Name English
FURTRETHONIUM P-TOLUENESULFONATE [MI]
Common Name English
FURFURYLTRIMETHYLAMMONIUM P-TOLUENESULFONATE
Common Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, SALT WITH 4-METHYLBENZENESULFONIC ACID (1:1)
Systematic Name English
FURTRETHONIUM TOSILATE
Common Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, 4-METHYLBENZENESULFONATE (1:1)
Systematic Name English
Code System Code Type Description
MERCK INDEX
M5611
Created by admin on Sat Jun 26 04:39:55 UTC 2021 , Edited by admin on Sat Jun 26 04:39:55 UTC 2021
PRIMARY
FDA UNII
15H5ION32Q
Created by admin on Sat Jun 26 04:39:55 UTC 2021 , Edited by admin on Sat Jun 26 04:39:55 UTC 2021
PRIMARY
PUBCHEM
20056781
Created by admin on Sat Jun 26 04:39:55 UTC 2021 , Edited by admin on Sat Jun 26 04:39:55 UTC 2021
PRIMARY
CAS
5978-73-4
Created by admin on Sat Jun 26 04:39:55 UTC 2021 , Edited by admin on Sat Jun 26 04:39:55 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY